Goldenwell Biotech, Inc.

Equities

GWLL

US38138N1046

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 13:01:50 2024-05-08 EDT			5-day change	1st Jan Change
0.2 ^USD	+241.30%		+241.30%	+241.30%

04-12	Goldenwell Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Goldenwell Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Goldenwell Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

April 12, 2024 at 06:04 am

Goldenwell Biotech, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 0.00234 million compared to USD 0.0478 million a year ago. Net loss was USD 0.116895 million compared to USD 0.985097 million a year ago.

Latest news about Goldenwell Biotech, Inc.

Goldenwell Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-12	CI
Goldenwell Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Goldenwell Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Goldenwell Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-19	CI
Goldenwell Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-13	CI
Goldenwell Biotech, Inc. Auditor Raises 'Going Concern' Doubt	23-04-12	CI
Goldenwell Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Goldenwell Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Goldenwell Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-18	CI
Goldenwell Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-01	CI
Goldenwell Biotech, Inc. Auditor Raises 'Going Concern' Doubt	22-03-31	CI
Goldenwell Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	22-01-03	CI

Chart Goldenwell Biotech, Inc.

Duration

Period

More charts

Company Profile

Goldenwell Biotech, Inc. is in the development stage whose purpose is research and development, production and sales health cares and supplements products. The Company is offering its products under two categories: Polypeptide Freeze-dried Powder and Solid Tablets Products. The Companyâs products are JI MAI-Bovine Cardiac Vascular Active Peptide, Double Proline AG- three-dimensional (3D) Active Collagen Peptide, Cartilage Peptide-Type II collagen peptide, Se Plus, and Sugar Master. Bovine cardiac vascular active peptide is a protein peptide of vascular homology (amino acid type and its sequence) which made from healthy and fresh bovine cardiac vascular tissues as raw materials. Its DPAG product is designed to be an easily absorbed bioactive collagen. Type II collagen peptide is prepared from Bovine or Pig Cartilage bones by hot water extraction. Its Sugar Master product is made utilizing low temperature extraction techniques to maximize the harvest of bio-actives of plant matter.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GOLDENWELL BIOTECH, INC.	+241.30%	19.8M
MODERNA, INC.	+23.37%	47.02B
LONZA GROUP AG	+49.84%	41.86B
IQVIA HOLDINGS INC.	-0.94%	41.76B
CELLTRION, INC.	-4.32%	28.8B
ICON PUBLIC LIMITED COMPANY	+11.29%	26.05B
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.15B
BIO-TECHNE CORPORATION	+3.20%	12.55B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B
MEDPACE HOLDINGS, INC.	+30.23%	12.34B

Other Biotechnology & Medical Research